ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) said the first patient in its Phase I-B clinical trial for systemic lupus erythematosus (SLE) was administered with the dose of treatment, according to a Thursday filing with the Hong Kong bourse.
IMM0306 attaches to two specific proteins, CD47 and CD20, found on cancerous B cells and sticks more to CD20 than to CD47, making the cancer treatment more effective, the filing said.
The pharma company's shares were up by over 16%.
Price (HKD): $7.25, Change: $+1.0, Percent Change: +16.19%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。